Please Wait.....
Report
Global Cell and Gene Therapy Market
Market Research Report I 2024-03-21 I 145 Pages I BCC Research
Description
Report Scope:
The scope of this study encompasses an investigation of the cell and gene therapy market. BCC Research analyzes cell and gene therapy market based on therapy type, product, application, and region. BCC determines the current market status in each segment, examines its impact on future needs, and presents growth forecasts over the next five years. The report provides a detailed analysis of the market's drivers, challenges, and opportunities. The report also covers market projections for 2028 and market shares for key market players. The report includes the company profiles of the key players with detailed information about their business segments, financials, product portfolios, and recent developments. The report also provides information on the emerging technologies, and new developments, ESG development and investment outlook.
Report Includes:
- 55 data tables and 26 additional tables
- An overview of the global market for cell and gene therapy
- Analysis of global market trends, featuring historical revenue data for 2020, 2021, and 2022, estimated figures for 2023, forecasts for 2028, and projections of compound annual growth rates (CAGRs) through 2028
- Evaluation of the current market's size and revenue growth prospects specific to cell and gene therapy, along with a market share analysis by therapy type, product, application, and geographic region
- An update on recent advances in vector biology, drug delivery technology and gene editing technologies such as CRISPR
- Coverage of novel therapeutic products and promising new technologies still in the development and testing stage, with as assessment of the probability that they will be commercialized successfully in the next five years
- Discussion on recent approvals, developments, emerging technologies, ESG, and an investment outlook
- Profiles of leading market participants, including Mallinckrodt PLC, Vericel Corp., Gilead Sciences Inc., Pharmicell Co. Ltd., and Bristol-Myers Squibb Co.
Executive Summary
Summary:
The total global market for cell and gene therapy was valued at $5.8 billion in 2022 and this market is anticipated to reach $23.3 billion by 2028.
The global cell and gene therapy market is anticipated to grow at a CAGR of 26.4% during the forecast period of 2023-2028. The increasing focus on developing advanced therapies for different therapeutic areas, and growing prevalence of chronic conditions such as cancer and rare diseases, are responsible for market growth.
The market has witnessed approval of therapies in 2022 and 2023. Treatments approved in 2022 include Adstiladrin from Ferring Pharmaceuticals, Hemgenix from CSL Behring and UniQure, Roctavian from Biomarin Pharmaceuticals, Elevidys from Sarepta and Roche, and Upstaza from PTC Therapeutics. Vyjuvek from Krystal Biotech and Lyfgenia from Bluebird Bio were approved in 2023. There are more companies which have submitted biologics license applications for their cell and gene therapy products and the approvals are expected in 2024, thus contributing to the growth of the market.
Products such as Kresladi from Rocket Pharmaceuticals and Fidanacogene elaparvovec from Pfizer have submitted the biologics license application (BLA) and are likely to get approval in March and April 2024.
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Market Value
Chapter 2 Market Overview
Cell and Gene Therapy Overview
Regulatory Landscape
U.S. (FDA)
Europe
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Market Restraints
Market Opportunities
Chapter 4 Market Segmentation Analysis
Segmentation Breakdown
Global Market for Cell and Gene Therapy
Market Size and Forecast
Market Analysis
Cell Therapy
Gene-modified Cell Therapy
Gene Therapy
Global Market for Gene-modified Cell Therapy and Gene Therapy by Vector Type
Market Size and Forecast
Market Analysis
Adeno-Associated Viral (AAV) Vectors
Retroviral Vectors
Lentiviral Vectors
Others
Global Market for Cell and Gene Therapy by Drug Product
Market Size and Forecast
Zolgensma
Yescarta
Kymriah
Abecma
Maci
Tecartus
Epicel
Others
Global Market for Cell and Gene Therapy by Application
Market Size and Forecast
Oncology
Rare Diseases
Ophthalmology
Other Therapeutic Areas
Geographic Breakdown
Global Market for Cell and Gene Therapy by Region
Market Size and Forecast
North America
Market Size and Forecast
U.S.
Canada
Mexico
Europe
Market Size and Forecast
Germany
U.K.
France
Rest of Europe
Asia-Pacific
Market Size and Forecast
Japan
Cina
Australia
Rest of Asia-Pacific
Rest of the World
Market Size and Forecast
Chapter 5 Competitive Intelligence
Investment Outlook
Mergers and Acquisitions
Competitive Landscape: Overview
Market Share Analysis
Strategic Acquisitions and Collaborations
Pipeline Analysis
Chapter 6 Sustainability: An ESG Perspective
Introduction
Conclusion
Chapter 7 Appendix
Methodology
Company Profiles
AMGEN INC.
BLUEBIRD BIO INC.
BRISTOL-MYERS SQUIBB CO.
DENDREON PHARMACEUTICALS LLC
FERRING PHARMACEUTICALS
GILEAD SCIENCES INC.
IOVANCE BIOTHERAPEUTICS INC.
JOHNSON & JOHNSON SERVICES INC.
KRYSTAL BIOTECH INC.
MALLINCKRODT PLC
NOVARTIS AG
ORCHARD THERAPEUTICS PLC.
PHARMICELL CO. LTD.
UNIQURE N.V.
VERICEL CORP.
Abbreviations
References
List of Tables
Summary Table : Global Market for Cell and Gene Therapy, by Type of Therapy, Through 2028
Table 1 : Approved Cell Therapy Products (Including Withdrawn Products), 2023
Table 2 : Approved Gene Therapy Products (Including Withdrawn Products), 2023
Table 3 : Total Number of New Cases and Deaths Due to Various Cancers Globally, 2020
Table 4 : Comparison of Accelerated Approvals for Various Drugs
Table 5 : Global Market for Cell and Gene Therapy, by Type of Therapy, Through 2028
Table 6 : Global Market for Cell Therapy, by Region, Through 2028
Table 7 : Approved CAR-T Products, as of December 2023
Table 8 : Global Market for Gene-modified Cell Therapy, by Region, Through 2028
Table 9 : Global Market for Gene Therapy, by Region, Through 2028
Table 10 : Global Market for Gene-modified Cell Therapy and Gene Therapy, by Vector Type, Through 2028
Table 11 : Global Market for Cell and Gene Therapy, by Drug Product, Through 2028
Table 12 : Global Market for Cell and Gene Therapy, by Application, Through 2028
Table 13 : Global Market for Cell and Gene Therapy for Oncology, by Region, Through 2028
Table 14 : Global Market for Cell and Gene Therapy for Rare Diseases, by Region, Through 2028
Table 15 : Global Market for Cell and Gene Therapy for Ophthalmology, by Region, Through 2028
Table 16 : Global Market for Cell and Gene Therapy for Other Therapeutic Areas, by Region, Through 2028
Table 17 : Global Market for Cell and Gene Therapy, by Region, Through 2028
Table 18 : North American Market for Cell and Gene Therapy, by Country, Through 2028
Table 19 : European Market for Cell and Gene Therapy, by Country, Through 2028
Table 20 : Asia-Pacific Market for Cell and Gene Therapy, by Country, Through 2028
Table 21 : Strategic Acquisitions and Collaborations Portfolio, 2021-2023
Table 22 : Total Number of Clinical Trials, by Indication, 2023 (Q3)
Table 23 : Key Cell and Gene Therapy Drug Candidates in Phase I Trials
Table 24 : Key Cell and Gene Therapy Drug Candidates in Phase II Trials
Table 25 : Key Cell and Gene Therapy Drug Candidates in Phase III Trials
Table 26 : Key Cell and Gene Therapy Drug Candidates in Supplemental Indication and Formulation Expansions
Table 27 : Cell and Gene Therapy Drug Awaiting Approvals
Table 28 : Environmental Initiatives, by Various Cell and Gene Therapy Companies
Table 29 : ESG Rankings for Companies in the Cell and Gene Therapy Market, 2023
Table 30 : Amgen Inc.: Company Snapshot
Table 31 : Amgen Inc.: Financial Performance, FY 2021 and 2022
Table 32 : Amgen Inc.: Product Portfolio
Table 33 : Amgen Inc: News/Key Developments, 2021
Table 34 : Bluebird Bio Inc.: Company Snapshot
Table 35 : Bluebird Bio Inc.: Financial Performance, FY 2021 and 2022
Table 36 : Bluebird Bio Inc.: Product Portfolio
Table 37 : Bluebird Bio Inc.: News/Key Developments,2022 and 2023
Table 38 : Bristol Myers Squibb Co.: Company Snapshot
Table 39 : Bristol-Myers Squibb Co.: Financial Performance, FY 2021 and 2022
Table 40 : Bristol-Myers Squibb Co.: Product Portfolio
Table 41 : Bristol-Myers Squibb Co: News/Key Developments, 2022 and 2023
Table 42 : Dendreon Pharmaceuticals LLC: Company Snapshot
Table 43 : Dendreon Pharmaceuticals LLC: Product Portfolio
Table 44 : Dendreon Pharmaceuticals LLC: News/Key Developments, 2021
Table 45 : Ferring Pharmaceuticals: Company Snapshot
Table 46 : Ferring Pharmaceuticals: Financial Performance, FY 2021 and 2022
Table 47 : Ferring Pharmaceuticals: Product Portfolio
Table 48 : Ferring Pharmaceuticals: News/Key Developments, 2022 and 2023
Table 49 : Gilead Sciences Inc.: Company Snapshot
Table 50 : Gilead Sciences Inc.: Financial Performance, FY 2021 and 2022
Table 51 : Gilead Sciences Inc.: Product Portfolio
Table 52 : Gilead Sciences Inc.: News/Key Developments, 2021-2023
Table 53 : Iovance Biotherapeutics Inc.: Company Snapshot
Table 54 : Johnson & Johnson Services Inc.: Company Snapshot
Table 55 : Johnson & Johnson Services Inc.: Financial Performance, FY 2021 and 2022
Table 56 : Johnson & Johnson Services Inc: Product Portfolio
Table 57 : Johnson & Johnson Services Inc: News/Key Developments, 2023
Table 58 : Krystal Biotech Inc.: Company Snapshot
Table 59 : Krystal Biotech Inc.: Product Portfolio
Table 60 : Mallinckrodt PLC: Company Snapshot
Table 61 : Mallinckrodt PLC: Financial Performance, FY 2021 and 2022
Table 62 : Mallinckrodt PLC: Product Portfolio
Table 63 : Mallinckrodt PLC: News/Key Developments, 2022 and 2023
Table 64 : Novartis AG: Company Snapshot
Table 65 : Novartis AG: Financial Performance, FY 2021 and 2022
Table 66 : Novartis AG: Product Portfolio
Table 67 : Novartis AG: News/Key Developments, 2021-2023
Table 68 : Orchard Therapeutics Plc.: Company Snapshot
Table 69 : Orchard Therapeutics Plc.: Financial Performance, FY 2021 and 2022
Table 70 : Orchard Therapeutic PLC: Product Portfolio
Table 71 : Orchard Therapeutic PLC: News/Key Developments, 2021-2023
Table 72 : Pharmicell Co. Ltd.: Company Snapshot
Table 73 : Pharmicell Co. Ltd.: Product Portfolio
Table 74 : Uniqure N.V.: Company Snapshot
Table 75 : Uniqure N.V.: Product Portfolio
Table 76 : Uniqure N.V.: News/Key Developments, 2023
Table 77 : Vericel Corp.: Company Snapshot
Table 78 : Vericel Corp.: Financial Performance, FY 2021 and 2022
Table 79 : Vericel Corp.: Product Portfolio
Table 80 : Vericel Corp.: News/Key Developments, 2022
Table 81 : Abbreviations
List of Figures
Summary Figure : Global Market for Cell and Gene Therapy, by Type of Therapy, 2020-2028
Figure 1 : Various Gene Therapy Strategies
Figure 2 : Administration Routes in Gene Therapy
Figure 3 : Cell Therapy Products-Regulatory Pathway
Figure 4 : Cell and Gene Therapy Market Dynamics
Figure 5 : Global Market for Cell and Gene Therapy, by Type of Therapy, 2020-2028
Figure 6 : Global Market Shares of Cell and Gene Therapy, by Type of Therapy, 2022
Figure 7 : Global Market for Cell Therapy, by Region, 2020-2028
Figure 8 : Global Market for Gene-modified Cell Therapy, by Region, 2020-2028
Figure 9 : Global Market for Gene Therapy, by Region, 2020-2028
Figure 10 : Global Market for Gene-modified Cell Therapy and Gene Therapy, by Vector Type, 2020-2028
Figure 11 : Global Market Shares of Gene-modified Cell Therapy and Gene Therapy, by Vector Type, 2022
Figure 12 : Global Market for AAV Vectors for Gene-modified Cell Therapy and Gene Therapy, 2020-2028
Figure 13 : Global Market for Retroviral Vectors for Gene-modified Cell Therapy and Gene Therapy, 2020-2028
Figure 14 : Global Market for Lentiviral Vectors for Gene-modified Cell Therapy and Gene Therapy, 2020-2028
Figure 15 : Global Market for Other Vectors Used in Gene-modified Cell Therapy and Gene Therapy, 2020-2028
Figure 16 : Global Market for Cell and Gene Therapy, by Drug Product, 2020-2028
Figure 17 : Global Market Shares of Cell and Gene Therapy, by Drug Product, 2022
Figure 18 : Global Market for Zolgensma Drug for Cell and Gene Therapy, 2020-2028
Figure 19 : Global Market for Yescarta Drug for Cell and Gene Therapy, 2020-2028
Figure 20 : Global Market for Kymriah Drug for Cell and Gene Therapy, 2020-2028
Figure 21 : Global Market for Abecma Drug for Cell and Gene Therapy, 2020-2028
Figure 22 : Global Market for Maci Drug for Cell and Gene Therapy, 2020-2028
Figure 23 : Global Market for Tecartus Drug for Cell and Gene Therapy, 2020-2028
Figure 24 : Global Market for Epicel Drug for Cell and Gene Therapy, 2020-2028
Figure 25 : Global Market for Other Types of Drugs Used for Cell and Gene Therapy, 2020-2028
Figure 26 : Global Market for Cell and Gene Therapy, by Application, 2020-2028
Figure 27 : Global Market Shares of Cell and Gene Therapy, by Application, 2022
Figure 28 : Global Market for Cell and Gene Therapy for Oncology, by Region, 2020-2028
Figure 29 : Global Market for Cell and Gene Therapy for Rare Diseases, by Region, 2020-2028
Figure 30 : Global Market for Cell and Gene Therapy for Ophthalmology, by Region, 2020-2028
Figure 31 : Global Market for Cell and Gene Therapy for Other Therapeutic Areas, by Region, 2020-2028
Figure 32 : Global Market for Cell and Gene Therapy, by Region, 2020-2028
Figure 33 : Global Market Shares of Cell and Gene Therapy, by Region, 2022
Figure 34 : North American Market Shares of Cell and Gene Therapy, by Country, 2022
Figure 35 : U.S. Market for Cell and Gene Therapy, 2020-2028
Figure 36 : Canadian Market for Cell and Gene Therapy, 2020-2028
Figure 37 : Mexican Market for Cell and Gene Therapy, 2020-2028
Figure 38 : European Market Shares of Cell and Gene Therapy, by Country, 2022
Figure 39 : German Market for Cell and Gene Therapy, 2020-2028
Figure 40 : U.K. Market for Cell and Gene Therapy, 2020-2028
Figure 41 : French Market for Cell and Gene Therapy, 2020-2028
Figure 42 : Rest of European Market for Cell and Gene Therapy, 2020-2028
Figure 43 : Asia-Pacific Market Shares of Cell and Gene Therapy, by Country, 2022
Figure 44 : Japanese Market for Cell and Gene Therapy, 2020-2028
Figure 45 : Chinese Market for Cell and Gene Therapy, 2020-2028
Figure 46 : Australian Market for Cell and Gene Therapy, 2020-2028
Figure 47 : Rest of Asia-Pacific Market for Cell and Gene Therapy, 2020-2028
Figure 48 : Rest of the World Market for Cell and Gene Therapy, 2020-2028
Figure 49 : Investments, by Year, 2017-2022
Figure 50 : Equity Offering and Venture Financing, 2021 and 2022
Figure 51 : Public and Private Companies Deal Value, 2021 and 2022
Figure 52 : Number of Deals, 2021 and 2022
Figure 53 : M&A Deals, 2021 and 2022
Figure 54 : Strategic Alliance Deals, 2021 and 2022
Figure 55 : Global Market Shares of Cell and Gene Therapy Drugs, by Company, 2022
Figure 56 : Total Number of Clinical Trials, by Phase, 2023 (Q3)
Figure 57 : Number of Cell and Gene Therapy Developers, by Region, 2023 (Q3)
Figure 58 : ESG in Cell and Gene Therapy Industry
Figure 59 : Amgen Inc.: Revenue Shares, by Business Unit, FY 2022
Figure 60 : Amgen Inc.: Revenue Shares, by Country/Region, FY 2022
Figure 61 : Bluebird Bio Inc.: Revenue Shares, by Business Unit, FY 2022
Figure 62 : Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2022
Figure 63 : Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2022
Figure 64 : Ferring Pharmaceuticals: Revenue Shares, by Business Unit, FY 2022
Figure 65 : Ferring Pharmaceuticals: Revenue Shares, by Country/Region, FY 2022
Figure 66 : Gilead Sciences Inc.: Revenue Shares, by Business Unit, FY 2022
Figure 67 : Gilead Sciences Inc.: Revenue Shares, by Country/Region, FY 2022
Figure 68 : Johnson & Johnson Services Inc.: Revenue Shares, by Business Unit, FY 2022
Figure 69 : Johnson & Johnson Services Inc.: Revenue Shares, by Country/Region, FY 2022
Figure 70 : Mallinckrodt PLC: Revenue Shares, by Business Unit, FY 2022
Figure 71 : Mallinckrodt PLC: Revenue Shares, by Country/Region, FY 2022
Figure 72 : Novartis AG: Revenue Shares, by Business Unit, FY 2022
Figure 73 : Novartis AG: Revenue Shares, by Country/Region, FY 2022
Figure 74 : Orchard Therapeutic PLC: Revenue Shares, by Business Unit, FY 2022
Figure 75 : Orchard Therapeutic PLC: Revenue Shares, by Country/Region, FY 2022
Figure 76 : Vericel Corp.: Revenue Shares, by Business Unit, FY 2022
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security